Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.
Giacomo Tini MelatoGiuliano TocciAllegra BattistoniMatteo SarocchiCamilla PietrantoniDomitilla RussoBeatrice MusumeciCarmine SavoiaMassimo VolpePaolo SpallarossaPublished in: Current heart failure reports (2023)
Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.
Keyphrases
- arterial hypertension
- end stage renal disease
- chronic kidney disease
- healthcare
- public health
- blood pressure
- ejection fraction
- rectal cancer
- newly diagnosed
- mental health
- case report
- radical prostatectomy
- peritoneal dialysis
- oxidative stress
- palliative care
- climate change
- risk assessment
- combination therapy
- patient reported